Holly Schmidt serves as a Principal Scientist at Bristol Myers Squibb, where she leverages her extensive expertise in protein biochemistry and engineering to drive the development of high-quality, fit-for-purpose proteins. In her current role, Holly leads cross-functional teams focused on optimizing the expression, purification, modification,...
Holly Schmidt serves as a Principal Scientist at Bristol Myers Squibb, where she leverages her extensive expertise in protein biochemistry and engineering to drive the development of high-quality, fit-for-purpose proteins. In her current role, Holly leads cross-functional teams focused on optimizing the expression, purification, modification, and analysis of various reagents and diagnostic tools, as well as early-stage drug candidates. Her commitment to delivering biophysically and biochemically robust tool and candidate molecules is pivotal for the success of early discovery programs, ensuring that they meet the stringent requirements of modern therapeutic development.
Holly's work encompasses a diverse array of projects, including the development of high-throughput (HT) and middle-scale processes for alternative formatted molecules such as multi-specific monoclonal antibodies (mAbs), single-chain variable fragments (scFv), Fc fusions, Adnectins, and antibody-drug conjugates. Her ability to navigate the complexities of protein expression and purification, coupled with her proficiency in biophysical analysis, allows her to contribute effectively to interdisciplinary teams aimed at achieving program goals.
Beyond her technical acumen, Holly is passionate about fostering a collaborative and supportive work environment. She prioritizes team building and project management, ensuring that her teams are not only capable of meeting deliverable goals but also maintaining a healthy work-life balance. This holistic approach not only enhances productivity but also cultivates a culture of innovation and excellence within her teams, positioning Bristol Myers Squibb at the forefront of biopharmaceutical advancements.
